Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Blood (2019) 134 (Supplement_1): 3475.

https://doi.org/10.1182/blood-2019-123948

Published: 2019

Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

John M Burke, MD, Marc André, Bruce D. Cheson, MD, Johannes Duell, MD, Grzegorz Nowakowski, MD, Andreas Rosenwald, MD, Gilles A. Salles, MD PhD, Jeff P. Sharman, MD, Philipp Bernhard Staber, MD PhD, Marek Trněný, MD, Jason R. Westin, MD, Wolfram Brugger, Günter Fingerle-Rowson, MD PhD, Magdalena Klanova, Guido Würth, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 2877.

https://doi.org/10.1182/blood-2019-128021

Published: 2019

Journal Articles

Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro

Paulina Horvei, MD, Reona Sakemura, MD PhD, Michelle J. Cox, Michael W. Ruff, MD, Mehrdad Hefazi, MD, Erin E. Tapper, Kendall J. Schick, Claudia Manriquez Roman, Charles J. Kuhlmann, Juergen Schanzer, Jan Endell, Grzegorz Nowakowski, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 2859.

https://doi.org/10.1182/blood-2019-130506

Published: 2019

Journal Articles

Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

Patrizia Mondello, MD PhD MSc, Angelo Fama, MD, Melissa C Larson, Zhi-Zhang Yang, MD, Jose C Villasboas, Andrew L. Feldman, MD, Susan L Slager, PhD, Brian K. Link, MD, Sergei Syrbu, MD PhD, Anne J Novak, PhD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz Nowakowski, MD, James R. Cerhan, MD PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 121.

https://doi.org/10.1182/blood-2019-126233

Published: 2019

Journal Articles

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

N. Nora Bennani, MD, Levi D Pederson, Pamela Atherton, Ivana Micallef, MD, Joseph P. Colgan, MD, Gita Thanarajasingam, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Stephen M Ansell, MD

Blood (2019) 134 (Supplement_1): 467.

https://doi.org/10.1182/blood-2019-126194

Published: 2019

Journal Articles

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Melissa C Larson, MS, Cristine Allmer, BS, Susan L. Slager, PhD, Thomas M. Habermann, MD, Sunnia T Chen, BS, Hector R Villarraga, MD, Joerg Herrmann, MD, Gita Thanarajasingam, MD, Alessia Castellino, MD, Grzegorz Nowakowski, MD, David J Inwards, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2019) 134 (Supplement_1): 422.

https://doi.org/10.1182/blood-2019-127203

Published: 2019

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 347.

https://doi.org/10.1182/blood-2019-122461

Published: 2019

Journal Articles

Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Blood (2019) 134 (Supplement_1): 400.

https://doi.org/10.1182/blood-2019-124017

Published: 2019

Journal Articles

Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience

Mattia Novo, Grzegorz Nowakowski, MD, Ivana Micallef, MD, Rebecca L. King, MD, Robert Spinner, MD, Kay M. Ristow, BS, Thomas M. Habermann, MD, Patrick Johnston, MD PhD

Blood (2019) 134 (Supplement_1): 4129.

https://doi.org/10.1182/blood-2019-131378

Published: 2019

Journal Articles

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

N. Nora Bennani, MD, Grzegorz Nowakowski, MD, Lisa M. Rimsza, MD, Alex A Adjei, MD PhD, Laurence Doyle, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 4090.

https://doi.org/10.1182/blood-2019-129104

Published: 2019

Journal Articles

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Donald Berry, PhD, Kristine Broglio, MS, Carol Ward, MSc, Federico Mattiello, PhD, Deniz Sahin, BSc, Tina G Nielsen, MD PhD, Anna McGlothlin, PhD, Corrine Elliott, MS, Thomas E. Witzig, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Maurizio Martelli, MD, Lale Kostakoglu, MD MPH, Grzegorz Nowakowski, MD

Blood (2019) 134 (Supplement_1): 4101.

https://doi.org/10.1182/blood-2019-124067

Published: 2019

Journal Articles

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Blood (2019) 134 (Supplement_1): 4092.

https://doi.org/10.1182/blood-2019-123083

Published: 2019

Journal Articles

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Anas Younes, MD, Grzegorz Nowakowski, MD, Allison C. Rosenthal, DO, Lori A. Leslie, MD, Han W. Tun, MD, Matthew A. Lunning, DO, FACP, Iris Isufi, MD, Robert Martell, MD PhD, Krish Patel, MD

Blood (2019) 134 (Supplement_1): 5327.

https://doi.org/10.1182/blood-2019-131851

Published: 2019

Journal Articles

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Sunnia T Chen, BS, Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Cristine Allmer, BS, Dennis P. Robinson, Grzegorz Nowakowski, MD, Thomas M. Habermann, MD, Susan L Slager, PhD, Carrie A. Thompson, MD, James R. Cerhan, MD PhD

Blood (2019) 134 (Supplement_1): 5215.

https://doi.org/10.1182/blood-2019-128775

Published: 2019

Journal Articles

Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1

Jun Zhu, MD PhD, Grzegorz Nowakowski, MD, Qingyuan Zhang, Joshua Brody, MD, Xiuhua Sun, MD, Joseph Maly, MD, Yuqin Song, MD PhD, Yongping Song, MD PhD, Jennifer Kimberly Lue, MD, Wen Luo, PhD, Lei Zhang, MD, Isabel Han, Manoj Jivani, Young Liu, Ling Li, MD, Joan Sun, MBA, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 5330.

https://doi.org/10.1182/blood-2019-124930

Published: 2019

Journal Articles

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

Pedro Horna, MD, Grzegorz Nowakowski, MD, Jan Endell, Rainer Boxhammer

Blood (2019) 134 (Supplement_1): 5345.

https://doi.org/10.1182/blood-2019-129600

Published: 2019

Journal Articles

Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy

Sonia Fortin Gamero, MD, Yi Lin, MD PhD, Saad S. Kenderian, MD, N. Nora Bennani, MD, Gita Thanarajasingam, MD, Thomas M. Habermann, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 5352.

https://doi.org/10.1182/blood-2019-131080

Published: 2019

Journal Articles

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Sangeetha Gandhi, MBBS, N. Nora Bennani, MD, Sonia Fortin, Thomas M. Habermann, MD, Patrick Johnston, MD, James R. Cerhan, MD PhD, Kay M. Ristow, BS, Carrie A. Thompson, MD, Grzegorz Nowakowski, MD, Yi Lin, MD PhD, Jose C Villasboas, MD, Luis Porrata, MD, Thomas E. Witzig, MD, Ivana Micallef, MD, David J Inwards, MD, Stephen M Ansell, MD PhD, Jonas Paludo, MD

Blood (2019) 134 (Supplement_1): 5293.

https://doi.org/10.1182/blood-2019-131965

Published: 2019

Journal Articles

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

Blood (2019) 134 (Supplement_1): 1532.

https://doi.org/10.1182/blood-2019-131442

Published: 2019

Journal Articles

Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma

Namrata Singh, MD, Sarah L Mott, Ashley Noel McCarthy, MPH, Sergei Syrbu, MD PhD, Thomas M. Habermann, MD, Andrew L. Feldman, MD, Susan L Slager, PhD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Umar Farooq, MD, James R. Cerhan, MD PhD, Zuhair Ballas, Brian K. Link, MD

Blood (2019) 134 (Supplement_1): 1604.

https://doi.org/10.1182/blood-2019-122737

Published: 2019

NARROW

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro

Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only